AbstractsBreast cancer, metastatic299P - The prevalence of PIK3CA mutations in HR+/HER2– metastatic breast cancer (BELLE2, BELLE3 and BOLERO2 clinical trials)
Breast cancer, metastatic
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2018 THE AUTHORS. Published by Elsevier Ltd. All rights reserved.